Dr. Lieberman, of Harvard Medical School, is a prominent expert on RNAi delivery for therapeutic uses; Dr. Courvalin, of the Institut Pasteur,
Paris, France, is foremost authority on bacterial genetic transfer
CAMBRIDGE, Mass., Oct. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that two of the leading scientists in RNA Interference (RNAi) and gene delivery have joined the company's scientific advisory board. Dr. Judy Lieberman, a professor at Harvard Medical School, is well-known for her pioneering work on RNAi delivery for clinical applications. Dr. Patrice Courvalin, who is Institut Pasteur professor and director of the French National Reference Center for Antibiotics, is a leading expert in molecular bacteriology and gene delivery.
"We are honored that Drs. Lieberman and Courvalin have agreed to join Cequent's scientific advisory board, which is chaired by Cequent Founder Chiang J Li, M.D.," said Cequent President and CEO, Peter Parker. "The two bring unparalleled expertise and experience in their respective areas of research so fundamental to our success. We continue to make great progress with our development programs for familial polyposis, human papilloma virus, and inflammatory bowel disease, and their input will be paramount as we advance our pipeline of RNAi drug candidates through preclinical development, regulatory submission, and into clinical trials."
Judy Lieberman, M.D. Ph.D., is professor of pediatrics at the Harvard
Medical School, director of the Division of AIDS at Harvard Medical School,
and a senior investigator in the Immune Disease Institute. She received a
Ph.D. in theoretical physics from Rockefeller University and completed her
M.D. in the joint Harvard-MIT Program in Health, Science and Technology.
Dr. Lieberman is board certified in internal medicine and haematology, a
|SOURCE Cequent Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved